Digoxin Use in Impaired Renal Function

Introduction to Digoxin Use

• The American Journal of Kidney Diseases recommends that digoxin should be used with caution in patients with renal impairment, with dose reduction required when GFR < 60 ml/min/1.73 m², and should be avoided in patients with end-stage renal disease (GFR < 15 ml/min/1.73 m²) unless absolutely necessary and with extremely close monitoring 1, 2

Dosing Recommendations

• For patients with GFR < 60 ml/min/1.73 m², digoxin dose should be reduced and based on plasma concentrations 1
• For patients with GFR < 30 ml/min/1.73 m², significantly reduce the dose (by approximately 50-75%) and monitor levels closely 3

Monitoring and Toxicity Prevention

• Check serum digoxin concentrations early during therapy in patients with renal impairment 4
• Maintain therapeutic serum concentration between 0.6 and 1.2 ng/mL 4
• Monitor for signs of toxicity: confusion, nausea, anorexia, visual disturbances, and cardiac arrhythmias 3, 4
• Concomitant electrolyte abnormalities (especially hypokalemia) significantly increase toxicity risk 3, 4

Algorithm for Digoxin Use

• For patients with GFR > 60 ml/min/1.73 m², standard dosing (0.125-0.25 mg daily) is recommended 2
• For patients with GFR 30-60 ml/min/1.73 m², reduce dose by 25-50% (typically 0.0625-0.125 mg daily) 2
• For patients with GFR 15-30 ml/min/1.73 m², reduce dose by 50-75% (typically 0.0625 mg daily or every other day) 2

Digoxin Monitoring in Acute Kidney Injury

Monitoring Frequency Algorithm

• The American Journal of Kidney Diseases recommends monitoring renal function (creatinine, BUN) every 2-3 days in patients with GFR 30-60 mL/min/1.73 m² (Stage 3 CKD or mild-moderate AKI) 5
• The American Journal of Kidney Diseases suggests monitoring renal function daily in patients with GFR 15-30 mL/min/1.73 m² (Stage 4 CKD or moderate-severe AKI) 5

When to Resume Normal Monitoring Intervals

• The British Journal of Pharmacology guidelines state that once renal function stabilizes (creatinine stable for 3-5 days) and digoxin levels are consistently therapeutic, monitoring can be reduced to weekly, then monthly as per standard heart failure guidelines 6